Kidney

CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CareDx Inc. (NASDAQ: CDNA)

Retrieved on: 
Wednesday, July 6, 2022 - 6:30am

NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) between February 24, 2021, and May 5, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
  • CareDx is a diagnostics company that offers diagnostic testing services, products, and digital healthcare software for organ transplant patients and care providers.
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Retrieved on: 
Tuesday, July 5, 2022 - 9:05pm

SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a fireside chat and 1x1 meetings at the William Blair Biotech Focus Conference 2022.

Key Points: 
  • SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a fireside chat and 1x1 meetings at the William Blair Biotech Focus Conference 2022.
  • To access the webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinooks website.
  • Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases.
  • In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases.

Evergreen Nephrology Partners with Nephrology Associates of Michigan

Retrieved on: 
Tuesday, July 5, 2022 - 5:46pm

NASHVILLE, Tenn., July 5, 2022 /PRNewswire/ -- Evergreen Nephrology is announcing a joint venture with Nephrology Associates of Michigan, a specialty nephrology practice caring for patients in Southeast Michigan.  Evergreen Nephrology partners with nephrologists in local markets to transform kidney care, and Evergreen believes that nephrologists are best positioned to lead this charge.

Key Points: 
  • NASHVILLE, Tenn., July 5, 2022 /PRNewswire/ --Evergreen Nephrology is announcing a joint venture with Nephrology Associates of Michigan, a specialty nephrology practice caring for patients in Southeast Michigan.
  • Evergreen Nephrology partners with nephrologists in local markets to transform kidney care, and Evergreen believes that nephrologists are best positioned to lead this charge.
  • "It is our honor at Evergreen Nephrology to partner with Nephrology Associates of Michigan.
  • "Together, Evergreen Nephrology and Nephrology Associates of Michigan will change the way people living with kidney disease in Michigan receive care.

AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa’s Dual Protective Mechanism

Retrieved on: 
Tuesday, July 5, 2022 - 4:00pm

The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI.

Key Points: 
  • The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI.
  • The 1000 U/Kg dose tested in this study is, comparable to the dose currently being tested in the global phase III pivotal study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury (SA-AKI).
  • We are very encouraged by the findings of this study, as these data further validate the role of ilofotase alfa in protecting the kidney during episodes of acute kidney injury, said Maarten Kraan, MD, PhD, Chief Medical Officer of AM-Pharma.
  • Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year.

Propanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions

Retrieved on: 
Tuesday, July 5, 2022 - 2:00pm

Presently, there are 39 granted patents and a further 26 patent applications under examination in key global jurisdictions relating to proenzymes as an effective therapeutic agent against solid tumors, covering the lead product candidate, PRP.

Key Points: 
  • Presently, there are 39 granted patents and a further 26 patent applications under examination in key global jurisdictions relating to proenzymes as an effective therapeutic agent against solid tumors, covering the lead product candidate, PRP.
  • The Companys patent portfolio covers compositions of the PRP formulation and method of use claims for the treatment of solid tumors by targeting and eradicating cancer stem cells.
  • The fact there was limited prior art meant that our approach to cancer is unique if we could identify a novel formulation.
  • Over a decade later, we have filed multiple patents covering compositions of proenzymes and a method to treat metastatic cancer by targeting CSCs.

Walden Biosciences Announces Research Collaboration with University of Michigan

Retrieved on: 
Tuesday, July 5, 2022 - 2:00pm

CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that the Company has entered into a research collaboration with the University of Michigan at Ann Arbor (U-M) to advance cutting-edge research in the area of the genetics of soluble urokinase plasminogen activating receptor or suPAR.

Key Points: 
  • CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that the Company has entered into a research collaboration with the University of Michigan at Ann Arbor (U-M) to advance cutting-edge research in the area of the genetics of soluble urokinase plasminogen activating receptor or suPAR.
  • The research will be conducted through a collaboration with U-Ms Principal Investigator, Salim Hayek, M.D., a National Institute of Health-funded physician-scientist with expertise in renal disease, cardiovascular disease, and biomarker and risk prediction research.
  • Dr. Hayek is a member of Walden Biosciences Scientific Advisory Board.
  • Walden Biosciences is a private, venture-backed biopharmaceutical company focused on developing breakthrough medicines to reverse the progression of both rare and common forms of kidney disease.

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland

Retrieved on: 
Tuesday, July 5, 2022 - 1:05pm

Urovant Sciences and Pierre Fabre will share responsibility for vibegron clinical trials in the pediatric populations in Europe.

Key Points: 
  • Urovant Sciences and Pierre Fabre will share responsibility for vibegron clinical trials in the pediatric populations in Europe.
  • As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.
  • 2011;108(7):1132-1138. doi:10.1111/j.1464-410X.2010.09993.x
    UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.
  • PIERRE FABRE, the PIERRE FABRE logo are trademarks of Pierre Fabre Medicament SAS, registered in the U.S and in other countries.

Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations

Retrieved on: 
Tuesday, July 5, 2022 - 1:00pm

CAESAREA, Israel, July 5, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal ("ProSense"), today announced that Gilad Glick will serve as a strategic advisor to the Company, to guide its commercialization strategy up to execution. Mr. Glick will support the acceleration of IceCure's Go-to-Market operations for global adoption of ProSense® with a special focus on the U.S. and EU markets.

Key Points: 
  • Mr. Glick will support the acceleration of IceCure's Go-to-Market operations for global adoption of ProSense with a special focus on the U.S. and EU markets.
  • "Gilad is one of the world's leading medical device commercialization strategists and we look forward to working closely with him.
  • ProSense has tremendous potential across numerous medical indications in global markets, and we believe Gilad's expertise will add significant value to IceCure," stated IceCure CEO Eyal Shamir.
  • Mr. Glick was CEO of Itamar Medical from 2013 through 2022 when Itamar Medical was acquired by ZOLL Medical Corporation for $538 million.

Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)

Retrieved on: 
Tuesday, July 5, 2022 - 1:00pm

SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN).

Key Points: 
  • SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN).
  • The decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
  • We are pleased the European Commission has granted Chinook orphan drug designation in the EU for BION-1301 for IgA nephropathy, a serious, progressive disease for which there are limited treatment options, said Eric Dobmeier, chief executive officer of Chinook Therapeutics.
  • Chinooks lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Retrieved on: 
Tuesday, July 5, 2022 - 1:00pm

WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board’s Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board. Following these changes, Eloxx’s board is now comprised of five directors.

Key Points: 
  • Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board.
  • Following these changes, Eloxxs board is now comprised of five directors.
  • I am passionate about companies like Eloxx that are focused on addressing unmet needs for underserved patient populations.
  • I am excited to join the board of Eloxx and to contribute to the companys work in developing therapies for rare diseases, said Ms. Androski.